Literature DB >> 18954524

Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells.

Hung-hsing Chao1, Ju-chi Liu, Jia-wei Lin, Cheng-hsien Chen, Chieh-hsi Wu, Tzu-hurng Cheng.   

Abstract

AIM: Recent experimental and human studies have shown that hyperuricemia is associated with hypertension and cardiovascular diseases. Elevated levels of endothelin-1 (ET-1) has been regarded as one of the most powerful independent predictors of cardiovascular diseases. For investigating whether uric acidinduced vascular diseases are related to ET-1, the uric acid-induced ET-1 expression in human aortic smooth muscle cells (HASMC) was examined.
METHODS: Cultured HASMC treated with uric acid, cell proliferation and ET-1 expression were examined. Antioxidant pretreatments on uric acid-induced extracellular signal-regulated kinases (ERK) phosphorylation were carried out to elucidate the redox-sensitive pathway in proliferation and ET-1 gene expression.
RESULTS: Uric acid was found to increase HASMC proliferation, ET-1 expression and reactive oxygen species production. The ability of both N-acetylcysteine and apocynin (1-[4-hydroxy-3-methoxyphenyl]ethanone, a NADPH oxidase inhibitor) to inhibit uric acid-induced ET-1 secretion and cell proliferation suggested the involvement of intracellular redox pathways. Furthermore, apocynin, and p47phox small interfering RNA knockdown inhibited ET-1 secretion and cell proliferation induced by uric acid. Inhibition of ERK by U0126 (1,4-diamino-2,3-dicyano- 1,4-bis[2-aminophenylthio]butadiene) significantly suppressed uric acid-induced ET-1 expression, implicating this pathway in the response to uric acid. In addition, uric acid increased the transcription factor activator protein-1 (AP-1) mediated reporter activity, as well as the ERK phosphorylation. Mutational analysis of the ET-1 gene promoter showed that the AP-1 binding site was an important cis-element in uric acid-induced ET-1 gene expression.
CONCLUSION: This is the first observation of ET-1 regulation by uric acid in HASMC, which implicates the important role of uric acid in the vascular changes associated with hypertension and vascular diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18954524     DOI: 10.1111/j.1745-7254.2008.00877.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  27 in total

1.  Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial.

Authors:  Yongjun Shi; Wei Chen; Diana Jalal; Zhibin Li; Wenfang Chen; Haiping Mao; Qiongqiong Yang; Richard J Johnson; Xueqing Yu
Journal:  Kidney Blood Press Res       Date:  2011-11-23       Impact factor: 2.687

Review 2.  Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect?

Authors:  Ankoor Shah; Robert T Keenan
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

Review 3.  Uric acid and hypertension: cause or effect?

Authors:  Marilda Mazzali; Mehmet Kanbay; Mark S Segal; Mohamed Shafiu; Diana Jalal; Daniel I Feig; Richard J Johnson
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

Review 4.  Roles of hyperuricemia in metabolic syndrome and cardiac-kidney-vascular system diseases.

Authors:  Hongsha Wang; Haifeng Zhang; Lin Sun; Weiying Guo
Journal:  Am J Transl Res       Date:  2018-09-15       Impact factor: 4.060

5.  Uric acid level and erectile dysfunction in patients with coronary artery disease.

Authors:  Yalcin Solak; Hakan Akilli; Mehmet Kayrak; Alpay Aribas; Abduzhappar Gaipov; Suleyman Turk; Santos E Perez-Pozo; Adrian Covic; Kim McFann; Richard J Johnson; Mehmet Kanbay
Journal:  J Sex Med       Date:  2013-09-25       Impact factor: 3.802

Review 6.  Endothelin, hypertension and chronic kidney disease: new insights.

Authors:  Donald E Kohan
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-03       Impact factor: 2.894

7.  Combination of captopril and allopurinol retards fructose-induced metabolic syndrome.

Authors:  Carlos A Roncal; Sirirat Reungjui; Laura Gabriela Sánchez-Lozada; Wei Mu; Yuri Y Sautin; Takahiko Nakagawa; Richard J Johnson
Journal:  Am J Nephrol       Date:  2009-08-21       Impact factor: 3.754

8.  Could uric acid be a modifiable risk factor in subjects with pulmonary hypertension?

Authors:  Sergey I Zharikov; Erik R Swenson; Miguel Lanaspa; Edward R Block; Jawaharlal M Patel; Richard J Johnson
Journal:  Med Hypotheses       Date:  2010-01-12       Impact factor: 1.538

Review 9.  Uric acid in metabolic syndrome: From an innocent bystander to a central player.

Authors:  Mehmet Kanbay; Thomas Jensen; Yalcin Solak; Myphuong Le; Carlos Roncal-Jimenez; Chris Rivard; Miguel A Lanaspa; Takahiko Nakagawa; Richard J Johnson
Journal:  Eur J Intern Med       Date:  2015-12-15       Impact factor: 4.487

Review 10.  Comorbidities in patients with crystal diseases and hyperuricemia.

Authors:  Sebastian E Sattui; Jasvinder A Singh; Angelo L Gaffo
Journal:  Rheum Dis Clin North Am       Date:  2014-02-19       Impact factor: 2.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.